Terrie Curran

CIK: 0001690298

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (45.5%)

Position reduction

Option Exercises (M)3 (27.3%)

Derivative conversions

Awards (A)3 (27.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ARQT

Arcutis Biotherapeutics, Inc.

Director

PHAT

Phathom Pharmaceuticals, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

ARQT
Arcutis Biotherapeutics, Inc.
Aug 27, 2026
Exercise(M)
Direct
11.1K shares at avg. $7.51$84K
ARQT
Arcutis Biotherapeutics, Inc.
Aug 27, 2026
Sale(S)
Direct
11.1K shares at avg. $25.03$279K
ARQT
Arcutis Biotherapeutics, Inc.
Aug 27, 2026
Exercise(M)
Direct
27.1K shares at avg. $8.63$233K
ARQT
Arcutis Biotherapeutics, Inc.
Aug 27, 2026
Sale(S)
Direct
27.1K shares at avg. $25.03$677K
ARQT
Arcutis Biotherapeutics, Inc.
Aug 20, 2026
Sale(S)
Direct
1.1K shares at avg. $26.04$28K
ARQT
Arcutis Biotherapeutics, Inc.
Aug 20, 2026
Exercise(M)
Direct
1.1K shares at avg. $7.51$8K
ARQT
Arcutis Biotherapeutics, Inc.
Jun 5, 2026
Award(A)
Direct
5.8K shares-
ARQT
Arcutis Biotherapeutics, Inc.
Jun 12, 2025
Award(A)
Direct
7.6K shares-
PHAT
Phathom Pharmaceuticals, Inc.
Feb 27, 2025
Award(A)
Stock Option (Right to Buy)
Direct
342.5K shares-
PHAT
Phathom Pharmaceuticals, Inc.
Jan 21, 2025
Sale(S)
Direct
19.1K shares at avg. $6.59$126K
ARQT
Arcutis Biotherapeutics, Inc.
Nov 11, 2024
Sale(S)
Direct
8.7K shares at avg. $10.85$94K

		Type	Shares	Price		Ownership
Aug 27, 2026	ARQT Arcutis Biotherapeutics, Inc.	Exercise(M)	11,148	$7.51	$83,721	Direct
Aug 27, 2026	ARQT Arcutis Biotherapeutics, Inc.	Sale(S)	11,148	$25.03	$279,028	Direct
Aug 27, 2026	ARQT Arcutis Biotherapeutics, Inc.	Exercise(M)	27,052	$8.63	$233,459	Direct
Aug 27, 2026	ARQT Arcutis Biotherapeutics, Inc.	Sale(S)	27,052	$25.03	$677,095	Direct
Aug 20, 2026	ARQT Arcutis Biotherapeutics, Inc.	Sale(S)	1,072	$26.04	$27,912	Direct
Aug 20, 2026	ARQT Arcutis Biotherapeutics, Inc.	Exercise(M)	1,072	$7.51	$8,051	Direct
Jun 5, 2026	ARQT Arcutis Biotherapeutics, Inc.	Award(A)	5,778	-	$0	Direct
Jun 12, 2025	ARQT Arcutis Biotherapeutics, Inc.	Award(A)	7,609	-	-	Direct
Feb 27, 2025	PHAT Phathom Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	342,500	-	-	Direct
Jan 21, 2025	PHAT Phathom Pharmaceuticals, Inc.	Sale(S)	19,109	$6.59	$125,884	Direct
Nov 11, 2024	ARQT Arcutis Biotherapeutics, Inc.	Sale(S)	8,687	$10.85	$94,238	Direct

1-11 of 11 transactions

About Curran Terrie

Curran Terrie (SEC CIK 0001690298) files insider reports with the SEC as Director of Arcutis Biotherapeutics, Inc. (ARQT) and President and Chief Executive of Phathom Pharmaceuticals, Inc. (PHAT).

Signal8 holds 7 ownership filings by Curran Terrie, all Form 4s, filed between Nov 13, 2024 and Aug 28, 2026. Those filings report 11 transactions, from Nov 11, 2024 to Aug 27, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Curran Terrie's filings is in WESTLAKE VILLAGE, CA.

Recent filings by Curran Terrie

Aug 27, 2026: Option exercise of ARQT shares (Form 4, code M).
Aug 27, 2026: Open-market sale of ARQT shares (Form 4, code S).
Aug 27, 2026: Option exercise of ARQT shares (Form 4, code M).
Aug 27, 2026: Open-market sale of ARQT shares (Form 4, code S).
Aug 20, 2026: Open-market sale of ARQT shares (Form 4, code S).

Other insiders filing for Arcutis Biotherapeutics, Inc. (ARQT)

How to read Form 4 transaction codes